• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » QTc Prolongation Risk Management in Hospital Patients

QTc Prolongation Risk Management in Hospital Patients

March 1, 2018
Thomas Jordan, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Vandael E et al, J Clin Psychopharmacol 2017;37(5):540–545

Many of the medications we prescribe, most notably antipsychotics and antidepressants, have some risk of QTc prolongation. Since it’s rare to have complications of a prolonged QTc interval—such as torsades de pointes (TdP) and sudden cardiac death—clinics and hospitals typically don’t screen for it using electrocardiograms (ECG).

This study evaluated the impact of combining 2 medications that are known to cause QTc prolongation, and attempted to stratify patients based on a baseline risk score calculation. The study population consisted of 152 patients in 6 psychiatric hospitals who were already taking 1 or more QTc-prolonging medications. All patients received a baseline ECG to see whether their existing medication was causing QTc prolongation. These patients were then observed, and those whose clinicians added another torsadogenic medication were included in the study and were given another ECG within 14 days. The most common medications prescribed in the study were mirtazapine, quetiapine, escitalopram, and ­trazodone.

How did adding these medications affect ECGs? Across all patients, there was a statistically significant increase (p = 0.032) in mean QTc interval from a norm of 409.1 ms to 411.8 ms with a single QTc-prolonging medication. At follow-up ECG, after the addition of a second QTc-prolonging medication, only 3 participants (2%) developed a prolonged QTc (≥ 450 ms for men and ≥ 470 ms for women). Only 8 patients (6.6%) had an increase in their QTc ≥ 30 ms, and no one had an increase in QTc ≥ 60 ms. No study participants experienced TdP or sudden cardiac death.

The study also explored potential predictors of QTc prolongation by assigning a risk score at baseline. This score, called the “RISQ-PATH score,” was computed using the patient’s age, sex, cardiac risk factors, and number of QTc-prolonging medications currently prescribed.

According to the RISQ-PATH score, 58 patients (38.2%) were considered high risk at baseline, and these patients had a significantly higher QTc interval in the follow-up ECG compared to low-risk patients (420.7 ms vs 406.2 ms, p < 0.001).

TCPR’s Take
There is a direct correlation between the number of QTc-prolonging medications and a longer QTc interval. However, for most patients in this study, the absolute increase in QTc interval was very small, with only 2% of patients developing a prolonged QTc. And, regardless of the QTc prolongations, none of these patients developed any clinical symptoms attributable to the ECG changes. A risk score, such as the RISQ-PATH score, would be helpful in choosing which patients need ECG monitoring, but this test needs further validation before being used in the general psychiatric population. Also, despite these “reassuring” data, the problem may be greater among the elderly. For a geropsychiatrist, these data may not be reassuring.

The bottom line is that while combining QTc-prolonging medications does indeed affect QTc intervals, the magnitude of the effect is likely to be tiny, with a very low probability of clinical consequences. While prudence would dictate avoiding such combinations, if the patient’s symptoms require these medications, go ahead and prescribe them while monitoring the ECG.
General Psychiatry
KEYWORDS research-update
    Thomas Jordan, MD

    Do Psychosocial Interventions Improve Quality of Life in Advanced Dementia?

    More from this author
    www.thecarlatreport.com
    Issue Date: March 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Antipsychotics Update, TCPR, March 2018
    Note From the Editor-in-Chief
    Clozapine: A Fresh Look
    Abilify MyCite: Patient Care Breakthrough or Patent Extender?
    Prescribing and Managing Antipsychotics
    QTc Prolongation Risk Management in Hospital Patients
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.